AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7742714 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% hyperbaric oxygen (HBO) for 2 hours
Number of subjects: 26
Study 7742714 — intervention group
Group type: COMPARATOR
Intervention: 100% normobaric oxygen (NBO) for 2 hours
Number of subjects: 26
Study 2037209 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (three-hour duration, including small group discussion and role-playing exercises)
Number of subjects: 198
Study 6128098 — intervention group
Group type: EXPERIMENTAL
Intervention: bamethan
Number of subjects: 20
Study 6128098 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30859478 — intervention group
Group type: EXPERIMENTAL
Intervention: Double entry
Number of subjects: 412
Study 30859478 — intervention group
Group type: EXPERIMENTAL
Intervention: Solo read aloud
Number of subjects: 412
Study 30859478 — intervention group
Group type: COMPARATOR
Intervention: Partner read aloud
Number of subjects: 412
Study 30859478 — intervention group
Group type: COMPARATOR
Intervention: Visual checking
Number of subjects: 412
Study 31190575 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured using EQ‐5D‐5L questionnaires; mean utility was 0.88 per patient.
Number of subjects: 178
Study 31190575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis using iMTA medical consumption questionnaire (iMCQ) and iMTA productivity costs questionnaire (iPCQ); three-month mean societal cost per patient amounted to €3,211.
Number of subjects: 178
Study 29423865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume corticosteroid injections (HCI) - 10 mL total volume of 1% lidocaine plus 40 mg TA
Number of subjects: 52
Study 29423865 — intervention group
Group type: COMPARATOR
Intervention: Low-volume corticosteroid injections (LCI) - 4 mL total volume of 1% lidocaine plus 40 mg TA
Number of subjects: 52
Study 26860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ward-based program
Number of subjects: 24
Study 26860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-driven simulation-based strategy
Number of subjects: 24
Study 26860772 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 24
Study 24906419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 397
Study 24906419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 397
Study 24906419 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 397
Study 22245891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300mg/day
Number of subjects: 67
Study 22245891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100mg/day
Number of subjects: 67
Study 22245891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 22245891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (both doses)
Number of subjects: 67
Study 20145196 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment intervention
Number of subjects: 0
Study 20145196 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 19019210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day Tibolone
Number of subjects: 91
Study 19019210 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Tibolone
Number of subjects: 91
Study 19019210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 15814585 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health screening and health discussions
Number of subjects: 3464
Study 15814585 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-invited subjects)
Number of subjects: 3464
Study 11918884 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hepatic vascular exclusion (THVE)
Number of subjects: 0
Study 11918884 — intervention group
Group type: COMPARATOR
Intervention: Selective hepatic vascular exclusion (SHVE)
Number of subjects: 0
Study 10386418 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart revascularization (off pump)
Number of subjects: 80
Study 10386418 — intervention group
Group type: COMPARATOR
Intervention: Conventional revascularization with CPB at normothermia and cardioplegic arrest (on pump)
Number of subjects: 80
Study 8880942 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 mg BID)
Number of subjects: 8
Study 8880942 — intervention group
Group type: COMPARATOR
Intervention: placebo (0 mg BID)
Number of subjects: 8
Study 1993229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured allogenic epithelial grafts (CAGs)
Number of subjects: 0
Study 1993229 — intervention group
Group type: EXPERIMENTAL
Intervention: OpSite (commercially available dressing)
Number of subjects: 0
Study 1993229 — intervention group
Group type: COMPARATOR
Intervention: CAGs
Number of subjects: 0
Study 6394505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous penicillin therapy
Number of subjects: 60
Study 6394505 — intervention group
Group type: COMPARATOR
Intervention: Oral penicillin therapy
Number of subjects: 60
Study 31479120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of mesenchymal precursor cells
Number of subjects: 0
Study 31479120 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29106898 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Attention (FA) intervention
Number of subjects: 0
Study 29106898 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Monitoring (OM) intervention
Number of subjects: 0
Study 29106898 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26346687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 3%, Vitamin A 0.1%, Vitamin E 0.5%
Number of subjects: 100
Study 26346687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26861164 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration after four prior administrations of apomorphine
Number of subjects: 0
Study 26861164 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration after two, three, or four prior administrations of apomorphine
Number of subjects: 0
Study 26861164 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration for the first time
Number of subjects: 0
Study 22872229 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP (Therapie Aktiv)
Number of subjects: 801
Study 22872229 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 801
Study 20597828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump therapy (SAP group)
Number of subjects: 20
Study 20597828 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (Control group)
Number of subjects: 20
Study 18367559 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI)
Number of subjects: 50
Study 18367559 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy (WLE)
Number of subjects: 50
Study 16266358 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (800 mg daily)
Number of subjects: 4
Study 14562135 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture specific against erectile dysfunction (treatment group)
Number of subjects: 22
Study 14562135 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture specific against headache (placebo group)
Number of subjects: 22
Study 14562135 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with 50 mg sildenafil
Number of subjects: 22
Study 10687576 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 79
Study 10687576 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 79
Study 8739919 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 225
Study 8739919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 1747675 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions of pelvic floor exercises and bladder retraining supervised by a non-specialist nurse who had taken a three week course on assessing and treating uncomplicated incontinence.
Number of subjects: 7300
Study 1747675 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls with no intervention for three months).
Number of subjects: 7300
Study 6463176 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting deviant stimuli
Number of subjects: 0
Study 6463176 — intervention group
Group type: COMPARATOR
Intervention: Reading a comic book
Number of subjects: 0
Study 31170275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized cancellous bone allograft (MCBA)
Number of subjects: 21
Study 31170275 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone mineral (ABBM)
Number of subjects: 21
Study 31170275 — intervention group
Group type: COMPARATOR
Intervention: Anorganic equine bone mineral (AEBM)
Number of subjects: 21
Study 29108526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Treatment at Acute Crisis (STAC) plus Standard Care (SC)
Number of subjects: 40
Study 29108526 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 40
Study 27082758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse
Number of subjects: 30
Study 27082758 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture-Controlled (Kinect)
Number of subjects: 30
Study 27082758 — intervention group
Group type: COMPARATOR
Intervention: Oral Instructions to Third Person
Number of subjects: 30
Study 24126198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive patch method
Number of subjects: 100
Study 24126198 — intervention group
Group type: COMPARATOR
Intervention: Circumferential belt method
Number of subjects: 100
Study 22153770 — intervention group
Group type: EXPERIMENTAL
Intervention: FES‐CG (FES-assisted cycling)
Number of subjects: 20
Study 22153770 — intervention group
Group type: COMPARATOR
Intervention: CG (cycling only)
Number of subjects: 20
Study 18830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic fibrinolytic evacuation of intracerebral hemorrhage
Number of subjects: 0
Study 18830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase and tissue plasminogen activator for lysis
Number of subjects: 0
Study 18830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials evaluating the efficacy of stereotactic fibrinolysis
Number of subjects: 0
Study 17604143 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids at 2000 mg/day for 7 weeks
Number of subjects: 100
Study 17604143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17233786 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 10
Study 17233786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14984925 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study 11114313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² IV daily for 5 days every 28 days)
Number of subjects: 509
Study 11114313 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (40 mg/m² orally every 28 days)
Number of subjects: 509
Study 11114313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m²)
Number of subjects: 509
Study 11114313 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (40 mg/m²)
Number of subjects: 509
Study 11114313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 509
Study 9070491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy
Number of subjects: 332
Study 9070491 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 332
Study 8369211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulphate patch tests with a 10-step nickel sulphate dilution series (TRUE test)
Number of subjects: 72
Study 8369211 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 72
Study 8369211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulphate patch tests with high concentrations
Number of subjects: 72
Study 3790957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 per cent topical povidone-iodine solution in addition to systemic antibiotics (gentamicin and metronidazole)
Number of subjects: 315
Study 3790957 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics (gentamicin and metronidazole) without topical agent
Number of subjects: 315
Study 30395965 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 119
Study 30395965 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative mobilization program
Number of subjects: 119
Study 27681601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative DVD and standard preparation
Number of subjects: 123
Study 27681601 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 123
Study 25546255 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail follow-up reminders
Number of subjects: 334
Study 25546255 — intervention group
Group type: COMPARATOR
Intervention: Usual care discharge instructions
Number of subjects: 334
Study 23990706 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate emulsion group 1 (E1) - 10 μg · kg(‐1) · min(‐1) combined with remifentanil (0.1 μg · kg(‐1) · min(‐1))
Number of subjects: 110
Study 23990706 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate emulsion group 2 (E2) - 15 μg · kg(‐1) · min(‐1) combined with remifentanil (0.2 μg · kg(‐1) · min(‐1))
Number of subjects: 110
Study 23990706 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate emulsion group 3 (E3) - 20 μg · kg(‐1) · min(‐1) combined with remifentanil (0.2 μg · kg(‐1) · min(‐1))
Number of subjects: 110
Study 23990706 — intervention group
Group type: COMPARATOR
Intervention: Propofol group (P group) - 610 mg · kg(‐1) · h(‐1)
Number of subjects: 110
Study 20973889 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA implant
Number of subjects: 10
Study 20973889 — intervention group
Group type: COMPARATOR
Intervention: Collagen implant
Number of subjects: 10
Study 19248868 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation-only (n=16)
Number of subjects: 42
Study 19248868 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily therapy plus psychoeducation (n=15)
Number of subjects: 42
Study 19248868 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control; n=11)
Number of subjects: 42
Study 16729277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate every 2 months
Number of subjects: 1395
Study 16729277 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg ibandronate every 3 months
Number of subjects: 1395
Study 16729277 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg oral ibandronate daily
Number of subjects: 1395
Study 16729277 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1395
Study 16729277 — intervention group
Group type: EXPERIMENTAL
Intervention: All intravenous regimens
Number of subjects: 1395
Study 15367193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing mouthrinse
Number of subjects: 91
Study 15367193 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 91
Study 11343737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 40 mg daily
Number of subjects: 91
Study 11343737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 9587008 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-physician insertion of TCu380A IUD
Number of subjects: 367
Study 9587008 — intervention group
Group type: COMPARATOR
Intervention: Physician insertion of TCu380A IUD
Number of subjects: 367
Study 7988783 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II alleles, haplotypes and genotypes
Number of subjects: 0
Study 7988783 — intervention group
Group type: EXPERIMENTAL
Intervention: DR4 associated DRB1 and DQB1 alleles
Number of subjects: 0
Study 7988783 — intervention group
Group type: EXPERIMENTAL
Intervention: DPB1*0202
Number of subjects: 0
Study 7988783 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended haplotypes for DR2, DR11, and DR13
Number of subjects: 0
Study 7988783 — intervention group
Group type: EXPERIMENTAL
Intervention: DQA1/DQB1 genotypes (4SS heterodimers)
Number of subjects: 0
Study 2656929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin therapy
Number of subjects: 0
Study 2656929 — intervention group
Group type: COMPARATOR
Intervention: i.v. ceftazidime
Number of subjects: 0
Study 31874318 — intervention group
Group type: EXPERIMENTAL
Intervention: Seating chart intervention
Number of subjects: 1573
Study 31874318 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1573
Study 31668688 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (6 months)
Number of subjects: 25
Study 31668688 — intervention group
Group type: COMPARATOR
Intervention: Whole-body stretching (6 months)
Number of subjects: 25
Study 28541864 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 81
Study 28541864 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed primary closure
Number of subjects: 81
Study 28541864 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐assisted closure
Number of subjects: 81
Study 25923485 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry extract (BE) 480 mg/day
Number of subjects: 281
Study 25923485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 281
Study 23592479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration (300 min, supraphysiological dose)
Number of subjects: 10
Study 23592479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23592479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration
Number of subjects: 10
Study 21762197 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ+AMX (500 mg t.i.d.) for 14 days
Number of subjects: 51
Study 21762197 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ (400 mg t.i.d.) for 14 days
Number of subjects: 51
Study 21762197 — intervention group
Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 51
Study 19806062 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity better than 0.2 LogMAR
Number of subjects: 0
Study 19806062 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity between -0.2 and 0.6 LogMAR
Number of subjects: 0
Study 19806062 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity of 0.0 LogMAR or better
Number of subjects: 0
Study 19806062 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity equal to or worse than 0.7 LogMAR
Number of subjects: 0
Study 19806062 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity between 0.3 and 0.4 LogMAR
Number of subjects: 0
Study 17079372 — intervention group
Group type: EXPERIMENTAL
Intervention: Birmingham hip resurfacing
Number of subjects: 10
Study 17079372 — intervention group
Group type: COMPARATOR
Intervention: Nonresurfaced hips
Number of subjects: 10
Study 15043491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Decline evaluated through the Blessed Scale
Number of subjects: 100
Study 11251657 — intervention group
Group type: EXPERIMENTAL
Intervention: Stringent aspiration protocol (group S)
Number of subjects: 24
Study 11251657 — intervention group
Group type: COMPARATOR
Intervention: Non-stringent aspiration protocol (group NS)
Number of subjects: 24
Study 9249100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 2 mg x kg(‐1) x h(‐1)
Number of subjects: 32
Study 9249100 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 32
Study 7686100 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stents (14 French)
Number of subjects: 20
Study 7686100 — intervention group
Group type: COMPARATOR
Intervention: Metal stents (24 French)
Number of subjects: 20
Study 10285531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed booklet preoperative instruction
Number of subjects: 66
Study 10285531 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching performed by nurses after hospital admission
Number of subjects: 66
Study 10285531 — intervention group
Group type: COMPARATOR
Intervention: No instruction (control group)
Number of subjects: 66
Study 10285531 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 66
Study 30366067 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 2496
Study 30366067 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 2496
Study 29609630 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT)
Number of subjects: 50
Study 29609630 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 50
Study 29609630 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 50
Study 28807031 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 measured in plasma
Number of subjects: 41
Study 28807031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol measured in plasma
Number of subjects: 41
Study 28807031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoxin A4 measured in plasma
Number of subjects: 41
Study 28807031 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolvin D measured in plasma
Number of subjects: 41
Study 28807031 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 41
Study 26331623 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Sided Games (SSG)
Number of subjects: 17
Study 26331623 — intervention group
Group type: COMPARATOR
Intervention: Interval Training (IT)
Number of subjects: 17
Study 23414701 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsyndromal depression without comorbid anxiety disorders
Number of subjects: 247
Study 23414701 — intervention group
Group type: COMPARATOR
Intervention: Subsyndromal depression with comorbid anxiety disorders
Number of subjects: 247
Study 21514794 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 10010